Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:1376-1381
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:1376-1381.)
© 1997 American Heart Association, Inc.
Skipping of Exon 14 and Possible Instability of Both the mRNA and the Resultant Truncated Protein Underlie a Common Cholesteryl Ester Transfer Protein Deficiency in Japan
Takanari Gotoda;
Makoto Kinoshita;
Shun Ishibashi;
Toshimori Inaba;
Kenji Harada;
Masako Shimada;
Jun-ichi Osuga;
Tamio Teramoto;
Yoshio Yazaki;
;
Nobuhiro Yamada
From the Third Department of Internal Medicine, Faculty of Medicine,
University of Tokyo (T.G., S.I., T.I., K.H., M.S., J.O., Y.Y., N.Y.), and the
First Department of Internal Medicine, Teikyo University School of Medicine
(M.K., T.T.), Tokyo, Japan.
Correspondence to Takanari Gotoda, MD, Third Department of Internal Medicine, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Tokyo 113, Japan. E-mail tknrgtd-tky{at}umin.ac.jp
 |
Abstract
|
|---|
Abstract Among the Japanese population, a G-to-A mutation at
the
beginning of intron 14 of the human cholesteryl ester transfer
protein
(CETP) gene is a frequent cause of CETP deficiency
characterized
by markedly increased HDL cholesterol. The
resulting abnormalities
responsible for null CETP deficiency were
studied in detail.
The CETP mRNA transcripts amplified by polymerase
chain reaction
from the monocyte-derived macrophages of two
homozygous patients
were both found to be normal except for the whole
deletion of
exon 14. The deletion causes a shift of reading frame and
introduces
a premature termination codon downstream. Examination of the
macrophage
RNA from heterozygotes suggested the increased
instability of
the abnormal mRNA in the cytoplasm, because the amount
of the
aberrant transcript was nearly one third that of a normal
transcript
in the cytoplasm, while they were equal in the nucleus.
Although
this indicated the synthesis of a mutant CETP that lacks about
15%
at its carboxy terminus, immunoblot analysis
demonstrated that
the abnormal CETP was virtually absent in both the
media and
cell lysates of transfected COS-1 cells, which massively
expressed
the mutant CETP mRNA. These results elucidate the primary
abnormality
due to the common CETP splicing mutation to be the exon
skipping
of mRNA, which decreases the level of mRNA and produces a
truncated
protein that should be rapidly degraded intracellularly.
Key Words: high-density lipoproteins macrophages splicing mutation hyperalphalipoproteinemia exon skipping
 |
Introduction
|
|---|
The
plasma cholesteryl ester transfer protein (CETP) mediates
the transfer
of cholesteryl esters from HDL to other lipoproteins
and regulates
plasma HDL cholesterol levels.
1 The genetic
deficiency
of CETP was first described in 1985 in Japanese patients
with
complete absence of plasma CETP activity and markedly increased
levels
of HDL cholesterol.
2 3 The initial
probands were shown in 1989
to be homozygous for a G-to-A substitution
at the first nucleotide
of intron 14 of the human CETP
gene,
4 5 and subsequently, the
same point mutation was
also found in the CETP gene of many
other Japanese patients, suggesting
the causative effect of
the donor splice site
mutation.
6 7 8 9 10 However, the exact
mechanisms whereby the
mutation causes CETP deficiency have
remained to be elucidated,
although the mutation was assumed
to have a null allelic effect because
all homozygotes had no
detectable levels of CETP mass and activity in
the plasma.
4 5 6 7 The mutant allele is relatively common
among the Japanese
population, possibly by a founder
effect,
6 and would be present
in about 1% of the
normal Japanese population.
8 9 10
Similar donor splice site mutations have been reported in other human
genetic diseases, while the resultant changes were quite varied in
terms of mRNA and protein levels.11 12 13 14 15 The abundance of
the corresponding mRNA ranges from markedly decreased11 12
to normal levels.13 14 15 The pattern of aberrant splicing
includes the activation of nearby cryptic splice
sites,11 12 15 skipping of the preceding
exon,13 14 15 and retention of an unspliced intron in the
mature transcripts.15 The amounts of the protein mass,
which might reflect the synthesis, stability, and/or secretion of the
abnormal product, are also diverse.
In the present study, we clarify the molecular consequences of the
common CETP splicing mutation at both the mRNA and protein levels. The
results provide an insight into mRNA processing and suggest the
importance of the carboxy terminus of CETP in the maintenance
of the overall structure of the molecule.
 |
Methods
|
|---|
Patients
Two unrelated Japanese subjects were newly diagnosed as CETP
deficient
during examination of severe hyperalphalipoproteinemia and
were
shown to have total deficiency of plasma CETP activity and mass.
Their
HDL cholesterol levels were 4.45 and 6.44
mmol/L, respectively
(normal: 1.03 to 1.81 mmol/L).
The patients showed no abnormality
on physical examination and had no
familial history of consanguinity.
The study was approved by an
institutional review committee
and the study subjects gave
informed consent.
Gene Amplification by Polymerase Chain Reaction (PCR)
Human CETP is composed of 476 amino acids encoded by 16
exons.16 17 Gene fragments containing the exon 14intron
14 boundary were amplified by PCR from white blood cell DNA as done
previously.18 A pair of oligonucleotide
primers (primer J: 5'-AGCAGCTCCGAGTCCATCCAG-3' and primer K:
5'-AGTTTCCCCTCCAGCCCACA-3') were synthesized according to the published
data17 to amplify the fragments that covered from 73 bp
upstream to 24 bp downstream of the G-to-A substitution site.
mRNA Amplification by Reverse TranscriptionPCR (RT-PCR)
Monocyte-derived macrophages were prepared by culturing
human monocytes isolated from peripheral blood cells as
described elsewhere.12 Total cellular RNA was isolated
from differentiated macrophages, reverse transcribed, and
amplified by PCR as described previously.12 The reverse
transcription was performed with 15 pmol of 3'-outer primer (primer M:
5'-ACACCAGGGTTCCAGCTGTGA-3'). The total products were subjected to
the first PCR with 15 pmol of 5'-outer primer (primer A:
5'-GGGCCACTTACACACCAC-3'). To amplify the target regions, 1/1000 of the
first PCR products was subjected to the second PCR, together with
an appropriate pair of internal primers. Four cDNA fragments
(nucleotide positions 112 to 790, 737 to 1143, 1080 to
1249, and 1202 to 1659)16 that covered the entire coding
region of human CETP cDNA were amplified for each patient. Nuclear and
cytoplasmic RNAs were isolated separately from monocyte-derived
macrophages of two heterozygotes according to the method
reported previously.19
DNA Sequencing
DNA sequencing was performed in principle by direct sequencing
of DNA fragments amplified by asymmetrical PCR.18 Several
fragments were also sequenced after subcloning into the plasmid vector
Bluescript II (Stratagene).
Plasma CETP Activity and Mass
Plasma CETP activity was assayed as the rate of transfer of
[14C]cholesteryl ester from discoidal bilayer particle to
LDL as described previously.20 Plasma CETP mass was
measured by radioimmunoassay with monoclonal antibody against human
CETP (LT-A4) as described by Fukasawa et al.21
Construction of Expression Plasmids
A 1559-bp fragment (nucleotides 101 to 1659)
encompassing the entire coding sequence of human CETP cDNA was
amplified from normal macrophage RNA by the first PCR with Pfu
DNA polymerase (Stratagene). In the second PCR, 10 cycles of
amplifications were performed with mismatched primers A' and L' (primer
A': 5'-GGGAAGCTTACACACCACTGCCTGATA-3' and primer L':
5'-GTGCTTGCCTTCTTCTAGAAGCCC-3'), which introduced restriction sites
for HindIII and Xba I, respectively, at each end
of the DNA fragment. The fragment was digested with HindIII
and Xba I and transferred to the
HindIII/Xba I sites of the pRc/CMV vector
(Invitrogen). Subsequently, within this wild-type construct, a 686-bp
Sph IXba I segment (nucleotides 960
to 1643) was replaced by the corresponding segment amplified from the
patient's macrophage RNA. The integrity of these wild-type and
mutant expression plasmids was verified by DNA sequencing before
transfection into COS-1 cells.
In Vitro Expression of CETP in COS-1 Cells
COS-1 cells (8.0x106 cells) were transfected with
20 µg of purified plasmid DNA by lipofection with Lipofectin
(GIBCO-BRL) according to the manufacturer's instruction. The cells
were incubated in 8 mL of serum-free medium Opti-MEM (GIBCO-BRL) for 72
hours, and the medium was collected. The cells were harvested and
disrupted by sonication according to the procedure described by Wang et
al22 and resuspended in 50 µL of PBS containing 1
mmol/L PMSF.
Immunoblot and Northern Blot Analyses
Each culture medium (5 mL) or cell lysate (50 µL) was
incubated for 18 hours at 4°C with a mixture of four separate
monoclonal antibodies (5 µg protein per milliliter each), including
LT-A4, LT-F1, and LT-J1,21 as well as 2A-21, which was
raised against a synthetic peptide corresponding to amino acids 361 to
379 of human CETP.23 Pansorbin was then added to the
mixture to form immune complex as described previously.24
After centrifugation, the precipitates were washed
three times with PBS, resuspended in SDSpolyacrylamide gel
electrophoresis sample buffer, heated to 95°C for 5 minutes, and then
subjected to SDSpolyacrylamide gel electrophoresis followed
by transfer to a nitrocellulose membrane. CETP on the membrane was
reacted as described previously20 with monoclonal antibody
2A-21 or LT-A4. Northern blot analysis was performed as
described previously,12 with a probe of human CETP cDNA
fragment (737 to 1143) amplified by PCR.
 |
Results
|
|---|
The newly identified two patients had severe
hyperalphalipoproteinemia,
and their plasma contained no detectable
levels of CETP activity
and mass. Nucleotide sequence
analysis around the exon 14intron
14 boundary confirmed that
the two patients were homozygous
for a G-to-A substitution at the first
nucleotide of intron
14 (data not shown). The point
mutation disrupts the invariant
GT profile of the
eukaryotic 5'-donor splice site, which is
essential for
normal splicing of mRNA.
25
To investigate the resultant abnormality introduced into CETP mRNA,
monocyte-derived macrophages were employed as a source of CETP
mRNA.26 The mRNA was examined in detail by RT-PCR. Among a
series of experiments, the amplifications of the 3'-portions of cDNA
yielded distinctive results for normal samples and the patients'
samples (Fig 1
). Electrophoretic
analysis of the normal PCR products showed bands of the
expected sizes on ethidium bromidestained agarose gel. In contrast,
the same PCRs in the two patients either gave rise to a 73-bp-shorter
fragment or failed in the amplification (Fig 1A
). The results indicated
an identical aberrant splicing event in the CETP mRNA of the patients.
DNA sequencing of the 73-bp-shorter fragments revealed the complete
absence of exon 14 in the abnormal transcript, which was the result of
the direct splicing from exon 13 to exon 15 (Fig 2
). No other alteration was found in the
entire coding sequence of the CETP cDNA obtained from the patients.
Thus, it could be concluded that the skipping of exon 14 is a major
structural abnormality introduced into the CETP mRNA by the common
intron 14 donor splice site mutation.

View larger version (62K):
[in this window]
[in a new window]
|
Figure 1. Detection of aberrant splicing in the CETP mRNA of
the patients. A, PCR amplifications of three regions of CETP cDNA are
comparatively shown for a normal subject and the two patients. n
indicates normal; P1, patient 1; and P2, patient 2. Reaction
products were analyzed on 1.5% agarose gels with DNA
molecular size standards (molecular size standards [M],
øX174/Hae III). B, The locations of the six PCR primers
(primers H through M) used for amplifications are
represented schematically on the structure of the human
CETP gene (primer H: 5'-AATTCTTCAGTGATGGTGAA-3', primer I:
5'-CAACATTCTGTAGCTTACAC-3', primer J:
5'-AGCAGCTCCGAGTCCATCCAG-3', primer K: 5'-AGTTTCCCCTCCAGCCCACA-3',
primer L: 5'-GTGCTTGCCTTCTGCTACAA-3', and primer M:
5'-ACACCAGGGTTCCAGCTGTGA-3').
|
|

View larger version (73K):
[in this window]
[in a new window]
|
Figure 2. Comparison of the cDNA sequences coding for normal
and patient CETP. The autoradiograms represent
the nucleotide sequences of CETP cDNA from a normal subject
and a patient. The cDNA sequence from the patient revealed a whole
deletion of the 73 nucleotides that precisely correspond to
exon 14.
|
|
The relative abundance of the abnormal transcript was examined by the
competitive PCR method.27 Since both the normal 413-bp and
the abnormal 340-bp fragments can be coamplified with the same set of
primers (primers I and L), and their sizes vary only slightly,
coamplification of the two fragments is thought to occur in a
concentration-dependent manner. As shown in Fig 3A
, the similar levels of the two
fragments were obtained when RNAs of the normal subject and either
patient were mixed in the ratio of 1:3, implying that the abundance of
the abnormal transcript is about one third of that of the normal. In a
parallel experiment (Fig 3B
), the abundance of CETP mRNA in human
monocyte-derived macrophages was estimated to be about 1/30 of
that in the human liver, a principal source of CETP.1
Independently of these experiments, the CETP mRNA was also examined in
heterozygous subjects (Fig 4
). The result
confirmed that the level of the aberrantly spliced transcript is nearly
one third of that of the normal (Fig 4A
) and also showed that the
recently identified Asp442-to-Gly mutation underlying
partial CETP deficiency7 28 29 hardly influences mRNA
levels in vivo in contrast with the intron 14 splicing mutation (Fig 4B
).

View larger version (63K):
[in this window]
[in a new window]
|
Figure 3. Quantitation of CETP mRNA by the competitive PCR
method. A, RNAs isolated from monocyte-derived macrophages of a
normal subject and each patient were mixed in a series of ratios as
indicated, and the mixtures (1 µg RNA) were amplified by RT-PCR with
primers I and L. The relative amount of the two products (normal
413-bp and abnormal 340-bp bands) reflects the original contents of the
normal and mutant CETP mRNAs. n indicates normal; P1, patient 1; and
P2, patient 2. B, RNA isolated from the liver of a normal subject was
mixed in a series of ratios with that from monocyte-derived
macrophages of patient 1. The mixtures were coamplified as
described above.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Figure 4. Simultaneous amplification of both
normal and mutant CETP mRNA transcripts in heterozygotes. CETP mRNA
transcripts were amplified by RT-PCR from monocyte-derived
macrophages of two subjects who were heterozygous for the
intron 14 donor splice site mutation (A) or for the
Asp442-to-Gly mutation (B). In each panel, schematic
representation of the predicted structure of the normal and
mutant CETP cDNAs is given on the left, and electrophoretic
analysis on 1.5% agarose gels is shown on the right. Molecular
size standards (M) are øX174/Hae III. He indicates
heterozygotes. The PCR products in the heterozygote for the
Asp442-to-Gly mutation (B) were amplified using a
mismatched primer (primer N: 5'-AGCAAAGGCGTGAGCCTCGTC-3'), together
with primer L, and were subjected to digestion with restriction enzyme
Sal I.
|
|
To investigate the reason for the mRNA reduction, RNA was isolated
separately from nucleus and cytoplasm of monocyte-derived
macrophages of two unrelated individuals heterozygous for the
intron 14 splicing mutation. The result with the same RT-PCR method as
in Fig 4A
demonstrated that in both subjects, the amount of the
abnormal transcript was equal to that of the normal transcript in the
nucleus, although they differed significantly in the cytoplasm (Fig 5
). This observation provides evidence
that the mRNA reduction is not due to a reduced level of transcription
but probably to the increased instability of the mutant transcript in
the cytoplasm.

View larger version (35K):
[in this window]
[in a new window]
|
Figure 5. Amplification of CETP mRNA transcripts from nuclear
and cytoplasmic RNAs of heterozygotes. CETP mRNA transcripts were
amplified by RT-PCR from RNAs isolated separately from nucleus and
cytoplasm of monocyte-derived macrophages of two unrelated
heterozygotes for the intron 14 donor splice site mutation. The normal
458-bp and the mutant 385-bp bands were coamplified by the same RT-PCR
as in Fig 4A . Molecular size standards (M) are øX174/Hae
III. H1 indicates heterozygote 1 and H2, heterozygote 2.
|
|
Fig 6
shows the schematic
representation of the exon-skipping event, as well as the
predicted amino acid sequence of the mutant CETP. The skipping of exon
14 (73 bp) causes a shift of reading frame and introduces a premature
termination codon (TAG) three residues downstream. These changes lead
to the production of a mutant protein with a loss of 74 amino
acid residues at its carboxy terminus and with alterations in two of
its last three residues. Coupled with the observed expression of the
skipped mRNA (Figs 3 through 5

), this implies the synthesis of a
significant level of the truncated CETP in patients.

View larger version (29K):
[in this window]
[in a new window]
|
Figure 6. Exon skipping in patient CETP mRNA leading to a
shift of reading frame on translation. A, Diagram of the partial
genomic structure (exons 12 to 16) of the normal and patient CETP
genes. Exons are indicated by open boxes. The GT-to-AT change in the
donor splice site of intron 14 results in the ligation of exon 13 to
exon 15 during processing of the patient CETP mRNA. B, Comparison of
nucleotide sequences and predicted amino acid sequences for
the normal and mutant CETP. In the nucleotide sequence of
the patient cDNA, a TAG stop codon (underlined) is introduced into
position 403, due to the whole deletion of exon 14 and the concomitant
shift of reading frame. The amino acid residues altered by the
frameshift are marked with asterisks.
|
|
To elucidate the reason for the observed complete lack of CETP mass in
the patients' plasma, plasmids harboring the normal human CETP cDNA or
the mutant CETP cDNA lacking exon 14 were transiently expressed in
COS-1 cells, and the culture media and cell homogenates
were studied by immunoblot analysis with monoclonal
antibody 2A-21 (Fig 7
). The epitope of
2A-21 exists within the region encoded by exons 11 and 12 and thus
upstream of the skipped exon 14. The cells expressed comparable levels
of normal and mutant CETP mRNA transcripts (Fig 7A
). However,
immunoblot analysis showed that both the media and
the cell homogenates from cells transfected with the mutant
plasmid contained no detectable level of immunoreactive protein, while
those from cells with the normal plasmid had significant levels of
signals for CETP, with approximate molecular weight of 66 kD (Fig 7B
).
Similar results were also obtained with another antibody, LT-A4 (data
not shown). These results establish that the truncated mutant CETP
molecule resulting from the skipping of exon 14 appears neither inside
nor outside cells, most compatible with the extreme instability of the
mutant CETP polypeptide.

View larger version (71K):
[in this window]
[in a new window]
|
Figure 7. CETP expression in COS-1 cells transfected with the
normal (N) and mutant (M) expression vectors. A, Northern blot
analysis of total RNA from the transfected cells. The mutant
transcript is slightly smaller than the normal one, due to lack of exon
14. B, Immunoblot analysis of CETP in culture media
(left) and cell homogenates (right) of the transfected
cells. The signals for CETP with approximate molecular weight of 66 kD
were detected in both the medium and cell homogenates of
COS-1 cells transfected with the normal expression vector. Nonspecific
bands were also seen in the bottom of the blots.
|
|
 |
Discussion
|
|---|
Four separate CETP gene mutations have been published previously.
Of
the four mutations, the intron 14 donor splice site
mutation
4 and the Asp
442-to-Gly mutation in
exon 15
28 are both known
to be very common in the Japanese
population.
7 8 9 10 29 The
other two mutations, the
Gln
309-to-Stop mutation in exon 10
26 and a
1-bp insertion in intron 14,
7 are probably sporadic
mutations.
Except for the Asp
442-to-Gly mutation that
causes partial CETP
deficiency, the other three seemed to have null
allelic effects,
although exact mechanisms underlying the null effects
have not
been studied. In the present study, we demonstrated that
the
primary abnormality due to the intron 14 donor splice site mutation
is
the exon skipping of mRNA, which decreases the level of mRNA
and
produces a truncated protein that should be degraded intracellularly.
These
observations clearly explain the molecular basis of the complete
CETP
deficiency found not only in patients with the common intron
14
splicing mutation but also in a patient with the
Gln
309-to-Stop
mutation that leads to a larger truncation
of the carboxy terminus
of CETP.
There is increasing evidence that nonsense and frameshift mutations
that prematurely terminate mRNA translation decrease the corresponding
mRNA levels by poorly understood mechanisms.30 We
previously showed that the level of the mutant CETP mRNA transcript
with the Gln309-to-Stop mutation in exon 10 was about 1/10
that of the normal transcript.26 In this study, we found a
less severe reduction in the abundance of the mutant mRNA transcript
with skipping of exon 14, indicating that the introduction of a
premature stop codon at different positions of the same mRNA
transcripts could have different effects on the levels of mRNA. This
result also seems consistent with the notion that the closer a
mutation is to the 3' end of a gene the higher the levels of abnormal
mRNA.31 Decrease in the cytoplasmic mRNA pool can be
caused by reduction of any of transcription, nuclear mRNA stability,
mRNA transport from nucleus to cytoplasm, and cytoplasmic mRNA
stability. The mutant CETP mRNA with skipping of exon 14 would most
likely have a defect in the cytoplasmic stability, because its level
was reduced only in the cytoplasm and was normal in the nucleus. The
presence of the cytoplasmic pathways for the degradation of mRNA
containing nonsense codons has been shown in yeast.30
The functional importance of the carboxy terminus of CETP was first
indicated by the observation that a monoclonal antibody bound to the
last carboxy-terminal 26 amino acids of human CETP neutralizes the
cholesteryl ester transfer activity.32 Recently,
deletional and site-directed mutagenesis of the carboxy terminus of
CETP showed that amino acid residues 470 to 475 are directly involved
in neutral lipid binding and are essential for catalysis of cholesteryl
ester transfer.22 33 Thus, even if normally processed, the
mutant CETP with a deletion of residues 403 to 476 and alterations in
residues 400 and 402 in the patients would never be active in
cholesteryl ester transfer. Our results also indicated that the
carboxy-terminal region was important to secure the stability of CETP,
because the mutant CETP was virtually absent in the media and cell
lysates of transfected COS-1 cells. Interestingly, it was previously
shown that a mutant CETP lacking residues 411 to 476 is efficiently
expressed and stable in transfected insect cells.34 Taking
these results into consideration, it is conceivable that amino acids
within residues 400 to 410 are involved in the maintenance of
the overall structure of the CETP molecule.
In summary, our results demonstrated that the intron 14 donor splice
site mutation prevalent among Japanese patients with CETP deficiency
causes skipping of exon 14 and creation of a premature stop codon in
the mRNA transcript, whose abundance is significantly reduced. The
absence of the resulting truncated protein in the transfected cells
that massively expressed the mutant CETP mRNA provided a molecular
basis of complete CETP deficiency caused by this common CETP
mutation.
 |
Acknowledgments
|
|---|
We are indebted to Drs Masayoshi Fukasawa, Hiroyuki Arai, and
Keizo
Inoue for kindly providing anti-human CETP monoclonal antibodies,
Dr
Shin Ohnishi for the kind gift of human liver RNA, Dr Koichi
Kozaki
for technical assistance, and Drs Minoru Ohkubo and Toshio
Murase for
referring patients.
Received October 3, 1995;
accepted November 1, 1996.
 |
References
|
|---|
-
Tall A. Plasma lipid transfer
proteins. Annu Rev Biochem. 1995;64:235-257.[Medline]
[Order article via Infotrieve]
-
Koizumi J, Mabuchi H, Yoshimura A, Michishita I,
Takeda M, Itoh H, Sakai Y, Sakai T, Ueda K, Takeda R. Deficiency
of serum cholesteryl-ester transfer activity in patients with familial
hyperalphalipoproteinemia.
Atherosclerosis. 1985;58:175-186.[Medline]
[Order article via Infotrieve]
-
Kurasawa T, Yokoyama S, Miyake Y, Yamamura T, Yamamoto
A. Rate of cholesteryl ester transfer between high and low density
lipoproteins in human serum and a case with decreased transfer rate in
association with hyperalphalipoproteinemia. J Biochem.. 1985;98:1499-1508.[Abstract/Free Full Text]
-
Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C,
Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R, Tall
AR. Molecular basis of lipid transfer protein deficiency in a
family with increased high-density lipoproteins.
Nature. 1989;342:448-451.[Medline]
[Order article via Infotrieve]
-
Yamashita S, Hui DY, Sprecher DL, Matsuzawa Y, Sakai
N, Tarui S, Kaplan D, Wetterau JR, Harmony JAK. Total deficiency
of plasma cholesteryl ester transfer protein in subjects homozygous and
heterozygous for the intron 14 splicing defect. Biochem
Biophys Res Commun. 1990;170:1346-1351.[Medline]
[Order article via Infotrieve]
-
Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J,
Takata K, Maruhama Y, Mabuchi H, Tall AR. Increased high-density
lipoprotein levels caused by a common cholesteryl-ester transfer
protein gene mutation. N Engl J Med. 1990;323:1234-1238.[Abstract]
-
Inazu A, Jiang XC, Haraki T, Yagi K, Kamon N, Koizumi
J, Mabuchi H, Takeda R, Takata K, Moriyama Y, Doi M, Tall A.
Genetic cholesteryl ester transfer protein deficiency caused by two
prevalent mutations as a major determinant of increased levels of high
density lipoprotein cholesterol. J Clin
Invest. 1994;94:1872-1882.
-
Matsunaga A, Araki K, Moriyama K, Handa K, Arakawa F,
Nishi K, Sasaki J, Arakawa K. Detection of a point mutation in
cholesteryl ester transfer protein gene by polymerase chain
reaction mediated site-directed mutagenesis. Biochim
Biophys Acta. 1993;1166:131-134.[Medline]
[Order article via Infotrieve]
-
Inazu A, Koizumi J, Haraki T, Yagi K, Wakasugi T,
Takegoshi T, Mabuchi H, Takeda R. Rapid detection and prevalence
of cholesteryl ester transfer protein deficiency caused by intron 14
splicing defect in hyperalphalipoproteinemia. Hum
Genet. 1993;91:13-16.[Medline]
[Order article via Infotrieve]
-
Hirano K, Yamashita S, Funahashi T, Sakai N, Menju M,
Ishigami M, Hiraoka H, Kameda-Takemura K, Tokunaga K, Hoshino T,
Kumasaka K, Kawano K, Matsuzawa Y. Frequency of intron 14
splicing defect of cholesteryl ester transfer protein gene in the
Japanese general population: relation between the mutation and
hyperalphalipoproteinemia.
Atherosclerosis. 1993;100:85-90.[Medline]
[Order article via Infotrieve]
-
Treisman R, Orkin SH, Maniatis T. Specific
transcription and RNA splicing defects in five cloned ß-thalassaemia
genes. Nature. 1983;302:591-596.[Medline]
[Order article via Infotrieve]
-
Gotoda T, Yamada N, Murase T, Inaba T, Ishibashi S,
Shimano H, Koga S, Yazaki Y, Furuichi Y, Takaku F. Occurrence of
multiple aberrantly spliced mRNAs upon a donor splice site mutation
that causes familial lipoprotein lipase deficiency.
J Biol Chem. 1991;266:24757-24762.[Abstract/Free Full Text]
-
Marvit J, DiLella AG, Brayton K, Ledley FD, Robson KJH,
Woo SLC. GT to AT transition at a splice donor site causes
skipping of the preceding exon in phenylketonuria.
Nucleic Acids Res. 1987;15:5613-5628.[Abstract/Free Full Text]
-
Grandchamp B, Picat C, deRooij F, Beaumont C, Wilson P,
Deybach JC, Nordmann Y. A point mutation G
A in exon 12 of the
porphobilinogen deaminase gene results in exon skipping and is
responsible for acute intermittent porphyria. Nucleic
Acids Res. 1989;17:6637-6649.[Abstract/Free Full Text]
-
Kuivaniemi H, Kontusaari S, Tromp G, Zhao M, Sabol C,
Prockop DJ. Identical G+1 to A mutations in three different
introns of the type III procollagen gene (COL3A1) produce different
patterns of RNA splicing in three variants of Ehlers-Danlos syndrome,
IV: an explanation for exon skipping with some mutations and not
others. J Biol Chem. 1990;265:12067-12074.[Abstract/Free Full Text]
-
Drayna D, Jarnagin AS, McLean J, Henzel W, Kohr W,
Fielding C, Lawn R. Cloning and sequencing of human cholesteryl
ester transfer protein cDNA. Nature. 1987;327:632-634.[Medline]
[Order article via Infotrieve]
-
Agellon LB, Quinet EM, Gillette TG, Drayna DT, Brown
ML, Tall AR. Organization of the human cholesteryl ester
transfer protein gene. Biochemistry. 1990;29:1372-1376.[Medline]
[Order article via Infotrieve]
-
Gotoda T, Yamada N, Kawamura M, Kozaki K, Mori N,
Ishibashi S, Shimano H, Takaku F, Yazaki Y, Furuichi Y, Murase
T. Heterogeneous mutations in the human lipoprotein
lipase gene in patients with familial lipoprotein lipase
deficiency. J Clin Invest. 1991;88:1856-1864.
-
Memet S, Besançon F, Bourgeade MF.
Simultaneous and quantitative isolation of nuclear and
cytoplasmic RNA from eukaryotic cells. Trends
Genet. 1992;8:190.[Medline]
[Order article via Infotrieve]
-
Kinoshita M, Arai H, Fukasawa M, Watanabe T, Tsukamoto
K, Hashimoto Y, Inoue K, Kurokawa K, Teramoto T. Apolipoprotein
E enhances lipid exchange between lipoproteins mediated by cholesteryl
ester transfer protein. J Lipid Res. 1993;34:261-268.[Abstract]
-
Fukasawa M, Arai H, Inoue K. Establishment of
anti-human cholesteryl ester transfer protein monoclonal antibodies and
radioimmunoassaying of the level of cholesteryl ester transfer protein
in human plasma. J Biochem. 1992;111:696-698.[Abstract/Free Full Text]
-
Wang S, Wang X, Deng L, Rassart E, Milne RW, Tall
AR. Point mutagenesis of carboxyl-terminal amino acids of
cholesteryl ester transfer protein. J Biol
Chem. 1993;268:1955-1959.[Abstract/Free Full Text]
-
Sato T, Fukasawa M, Kinoshita M, Arai H, Saeki T,
Naraki T, Iwasaki Y, Teramoto T, Takahashi K, Saito Y, Inoue K.
Enzyme-linked immunosorbent assay for cholesteryl ester transfer
protein in human serum. Clin Chim Acta. 1995;240:1-9.[Medline]
[Order article via Infotrieve]
-
Teramoto T, Matsushima T, Kinoshita M, Watanabe T,
Hashimoto Y, Tsukamoto K, Katsuragawa K, Okazaki S, Yamanaka M.
Effect of chylomicron remnants on apolipoprotein E synthesis in HepG2
cells. Metabolism. 1994;43:44-50.[Medline]
[Order article via Infotrieve]
-
Mount SM. A catalogue of splice junction
sequences. Nucleic Acids Res. 1982;10:459-472.[Abstract/Free Full Text]
-
Gotoda T, Kinoshita M, Shimano H, Harada K, Shimada M,
Ohsuga J, Teramoto T, Yazaki Y, Yamada N. Cholesteryl ester
transfer protein deficiency caused by a nonsense mutation detected in
the patient's macrophage mRNA. Biochem Biophys
Res Commun. 1993;194:519-524.[Medline]
[Order article via Infotrieve]
-
Gilliland G, Perrin S, Blanchard K, Bunn HF.
Analysis of cytokine mRNA and DNA: detection and
quantitation by competitive polymerase chain reaction.
Proc Natl Acad Sci U S A. 1990;87:2725-2729.[Abstract/Free Full Text]
-
Takahashi K, Jiang XC, Sakai N, Yamashita S, Hirano K,
Bujo H, Yamazaki H, Kusunoki J, Miura T, Kussie P, Matsuzawa Y, Saito
Y, Tall A. A missense mutation in the cholesteryl ester transfer
protein gene with possible dominant effects on plasma high density
lipoproteins. J Clin Invest. 1993;92:2060-2064.
-
Sakai N, Yamashita S, Hirano K, Menju M, Arai T,
Kobayashi K, Ishigami M, Yoshida Y, Hoshino T, Nakajima N,
Kameda-Takemura K, Matsuzawa Y. Frequency of exon 15 missense
mutation (442D:G) in cholesteryl ester transfer protein gene in
hyperalphalipoproteinemic Japanese subjects.
Atherosclerosis. 1995;114:139-145.[Medline]
[Order article via Infotrieve]
-
Sachs AB. Messenger RNA degradation in
eukaryotes. Cell. 1993;74:413-421.[Medline]
[Order article via Infotrieve]
-
Frangi D, Cicardi M, Sica A, Colotta F, Agostoni A,
Davis AE III. Nonsense mutations affect C1 inhibitor
messenger RNA levels in patients with type I hereditary angioneurotic
edema. J Clin Invest. 1991;88:755-759.
-
Swenson TL, Hesler CB, Brown ML, Quinet E, Trotta PP,
Haslanger MF, Gaeta FCA, Marcel YL, Milne RW, Tall AR. Mechanism
of cholesteryl ester transfer protein inhibition by a neutralizing
monoclonal antibody and mapping of the monoclonal antibody
epitope. J Biol Chem. 1989;264:14318-14326.[Abstract/Free Full Text]
-
Wang S, Kussie P, Deng L, Tall A. Defective
binding of neutral lipids by a carboxyl-terminal deletion mutant of
cholesteryl ester transfer protein. J Biol
Chem. 1995;270:612-618.[Abstract/Free Full Text]
-
Au-Young J, Fielding CJ. Synthesis and secretion
of wild-type and mutant human plasma cholesteryl ester transfer protein
in baculovirus-transfected insect cells: the carboxyl-terminal region
is required for both lipoprotein binding and catalysis of
transfer. Proc Natl Acad Sci U S A. 1992;89:4094-4098.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
M. E. Lira, A. K. Loomis, S. A. Paciga, D. B. Lloyd, and J. F. Thompson
Expression of CETP and of splice variants induces the same level of ER stress despite secretion efficiency differences
J. Lipid Res.,
September 1, 2008;
49(9):
1955 - 1962.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Beuten, J. A.L. Gelfond, J. J. Byrne, I. Balic, A. C. Crandall, T. L. Johnson-Pais, I. M. Thompson, D. K. Price, and R. J. Leach
CYP1B1 variants are associated with prostate cancer in non-Hispanic and Hispanic Caucasians
Carcinogenesis,
September 1, 2008;
29(9):
1751 - 1757.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Alevizaki, K Saltiki, A Cimponeriu, I Kanakakis, N Xita, C C Alevizaki, I Georgiou, and H-L Sarika
Severity of cardiovascular disease in postmenopausal women: associations with common estrogen receptor {alpha} polymorphic variants
Eur. J. Endocrinol.,
April 1, 2007;
156(4):
489 - 496.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Yahata, J. Quan, N. Tamura, H. Nagata, T. Kurabayashi, and K. Tanaka
Association between single nucleotide polymorphisms of estrogen receptor {alpha} gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women
Hum. Reprod.,
July 1, 2005;
20(7):
1860 - 1866.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Herrington, T. D. Howard, G. A. Hawkins, D. M. Reboussin, J. Xu, S. L. Zheng, K. B. Brosnihan, D. A. Meyers, and E. R. Bleecker
Estrogen-Receptor Polymorphisms and Effects of Estrogen Replacement on High-Density Lipoprotein Cholesterol in Women with Coronary Disease
N. Engl. J. Med.,
March 28, 2002;
346(13):
967 - 974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Ohashi, S. Ishibashi, M. Yamamoto, J.-i. Osuga, Y. Yazaki, S. Yukawa, and N. Yamada
A Truncated Species of Apolipoprotein B (B-38.7) in a Patient With Homozygous Hypobetalipoproteinemia Associated With Diabetes Mellitus
Arterioscler. Thromb. Vasc. Biol.,
August 1, 1998;
18(8):
1330 - 1334.
[Abstract]
[Full Text]
[PDF]
|
 |
|